This Million Targets Drug: A $7M Bet on a CNS Breakthrough
A focused look at a $7 million wager on a CNS drug maker in Phase 3. Learn what this move signals about biotech momen...
Explore the best Visa credit card with rewards and no annual fee. Enjoy effortless earning on every transaction you make.
9,364 articlesA focused look at a $7 million wager on a CNS drug maker in Phase 3. Learn what this move signals about biotech momen...
When a major broker raises its bets on a fintech-insurer, investors take notice. This article breaks down the upgrade...
March brought a mix of regulatory headlines and upbeat AI-related gains. This article breaks down what happened in th...
Europe endures a third energy shock in four years, pressuring households and small businesses to rework budgets and s...
Gemini Space Station stock has faced a sharp weekly drop as analysts trim targets after a mixed earnings update. This...
Market bifurcation put Meta Platforms and Netflix on opposite growth tracks in early 2026. One path could double asse...
A soon-to-retire investor outlines a simple, income-centric ETF strategy built around three funds—JEPQ, DIVO, and SPH...
Investors are increasingly adding blue-chip art to mainstream portfolios to diversify beyond stocks and bonds. Fracti...
Three AI models weigh XRP vs Bitcoin for a $10,000 crypto bet in 2026. The forecasts highlight upside potential again...
Markets in early 2026 are pushing investors toward a core set of dividend stocks worth holding for life. The focus is...
As aging-in-place renovations gain momentum, Block Renovation’s Julie Kheyfets outlines how ADUs and revised financin...
A 48-hour ultimatum issued by President Trump to Iran over Hormuz triggers risk-off moves across markets. Energy pric...